NUVB Earnings Date: Nov 4, 2026 (Estimated) — Nuvation Bio Inc.
NYSE · Healthcare · Biotechnology
Updated
When is NUVB's next earnings date?
Nuvation Bio Inc. (NUVB) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.12 on revenue of $34.4M.
How did NUVB do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Nuvation Bio Inc. posted EPS of -$0.18 versus the -$0.14 estimate, a miss of 38.5%. Revenue was $31.7M against a $27.0M estimate. The stock's 1-day post-earnings move was -4.1%.
How much does NUVB stock move after earnings?
NUVB beat EPS estimates in 1 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About Nuvation Bio Inc.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.14 | -0.18 | -38.46% | $31.7M | ❌ Miss | -4.08% | +0.78% | +6.28% |
| 2026-05-04 | Q1 2026 | 0.06 | 0.01 | -83.33% | $83.2M | ❌ Miss | +9.52% | +7.94% | +7.03% |
| 2026-03-02 | Q4 2025 | -0.07 | -0.11 | -57.14% | $41.9M | ❌ Miss | -25.34% | -19.01% | -26.54% |
| 2025-11-03 | Q3 2025 | -0.16 | -0.16 | +0.00% | $13.1M | ➖ Inline | -6.58% | -10.25% | +61.90% |
| 2025-08-07 | Q2 2025 | -0.15 | -0.17 | -13.33% | $4.8M | ❌ Miss | -0.43% | +11.06% | +65.96% |
| 2025-03-06 | Q4 2024 | -0.14 | -0.15 | -7.14% | $5.7M | ❌ Miss | +6.88% | +16.93% | -12.17% |
| 2024-11-06 | Q3 2024 | -0.14 | -0.15 | -7.14% | $727,000 | ❌ Miss | +3.15% | +16.14% | +12.20% |
| 2024-05-14 | Q1 2024 | -0.10 | -0.07 | +30.00% | $0 | ✅ Beat | +0.00% | +3.03% | -9.39% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $31.7M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| Product | 73.2% | $23.2M | +1773.3% | $1.2M | $23.4M | $18.5M | $23.2M |
| License | 26.8% | $8.5M | +136.3% | $3.6M | $34.6M | $64.7M | $8.5M |
By region
Q2 FY26 · $31.7M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 73.2% | $23.2M | +1773.3% | — | — | $1.2M | $23.5M |
| CHINA | 25.2% | $8.0M | +135.0% | $5.1M | $2.9M | $3.4M | $3.1M |
| JAPAN | 1.6% | $504K | +109.1% | $2.1M | $200K | $241K | $28.4M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.